DrugAgent: Automating AI-aided Drug Discovery Programming through LLM Multi-Agent Collaboration
Reviewed by Pith T0 review T1 audit T2 compute T3 formal T4 kernel pith:IVKTSKINrecord.jsonopen to challenge →
read the original abstract
Recent progress in Large Language Models (LLMs) has drawn attention to their potential for accelerating drug discovery. However, a central problem remains: translating theoretical ideas into robust implementations in the highly specialized context of pharmaceutical research. This limitation prevents practitioners from making full use of the latest AI developments in drug discovery. To address this challenge, we introduce DrugAgent, a multi-agent framework that automates machine learning (ML) programming for drug discovery tasks. DrugAgent employs an LLM Planner that formulates high-level ideas and an LLM Instructor that identifies and integrates domain knowledge when implementing those ideas. We present case studies on three representative drug discovery tasks. Our results show that DrugAgent consistently outperforms leading baselines, including a relative improvement of 4.92% in ROC-AUC compared to ReAct for drug-target interaction (DTI). DrugAgent is publicly available at https://anonymous.4open.science/r/drugagent-5C42/.
This paper has not been read by Pith yet.
Forward citations
Cited by 8 Pith papers
-
Scalable Agentic Reasoning for Designing Biologics Targeting Intrinsically Disordered Proteins
StructBioReasoner is a scalable multi-agent system that designs IDP-targeting biologics, with over 50% of 787 candidates for Der f 21 showing better binding free energy than human-designed references.
-
Closed-loop Auto Research for Molecular Property Prediction: Discovering and Certifying Generalizable Improvements
Closed-loop LM-agent auto research finds some transferable gains on molecular property prediction benchmarks via external data but shows non-transfer for model and feature edits selected on validation.
-
Large Language Models Meet Biomedical Knowledge Graphs for Mechanistically Grounded Therapeutic Prioritization
DrugKLM integrates knowledge graphs and LLMs to prioritize mechanistically plausible drug repurposing candidates, outperforming baselines and aligning scores with improved survival signatures in cancer data.
-
MolClaw: An Autonomous Agent with Hierarchical Skills for Drug Molecule Evaluation, Screening, and Optimization
MolClaw deploys a hierarchical skill system (tool, workflow, and discipline levels) to achieve state-of-the-art results on MolBench tasks requiring 8 to 50+ sequential tool calls in drug discovery.
-
IR-Agent: Expert-Inspired LLM Agents for Structure Elucidation from Infrared Spectra
IR-Agent is a multi-agent LLM framework that emulates expert IR spectral analysis procedures to improve molecular structure elucidation accuracy and adaptability.
-
GenoMAS: A Multi-Agent Framework for Scientific Discovery via Code-Driven Gene Expression Analysis
GenoMAS deploys six specialized LLM agents with guided planning to preprocess transcriptomic data and identify genes, reaching 89.13% composite similarity and 60.48% F1 on the GenoTEX benchmark while outperforming pri...
-
MolClaw: An Autonomous Agent with Hierarchical Skills for Drug Molecule Evaluation, Screening, and Optimization
MolClaw deploys a hierarchical skill architecture to reach state-of-the-art results on a new benchmark of multi-step drug discovery tasks.
-
DrugPlayGround: Benchmarking Large Language Models and Embeddings for Drug Discovery
DrugPlayGround is a new benchmark framework for evaluating LLMs on text-based descriptions of physiochemical drug characteristics, synergism, drug-protein interactions, and physiological responses.
discussion (0)
Sign in with ORCID, Apple, or X to comment. Anyone can read and Pith papers without signing in.